W17
Gene TherapyMicrofluidics
Active

Indee Labs

Enabling T cell immunotherapy discovery, development and manufacturing

Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.

Ryan Pawell, CEO

My career aim is to use technology to improve health outcomes. Since deciding to pursue science in the startup environment, I've received various forms of backing from SOSV/IndieBio, Y Combinator, Founders Fund, Social+Capital, Main Sequences Ventures, Jobs for NSW, NSW Health, AusIndustry, MTP Connect, NSW Health Medical Device Fund, Australian Research Council along with an array of angel investors and µVCs also among others.

Ryan Pawell
Indee Labs